BRIEF-ARCA Biopharma And Oruka Therapeutics Announce Merger Agreement

Reuters

Apr 03, 2024

April 3 (Reuters) - ARCA Biopharma Inc :

* ARCA BIOPHARMA AND ORUKA THERAPEUTICS ANNOUNCE MERGER AGREEMENT

* ARCA BIOPHARMA AND ORUKA THERAPEUTICS ANNOUNCE MERGER AGREEMENT

* ARCA BIOPHARMA INC - UNDER TERMS OF MERGER AGREEMENT, PRE-MERGER ARCA STOCKHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 2.38% OF COMBINED COMPANY

* ARCA BIOPHARMA INC - COMBINED COMPANY PLANS TO OPERATE UNDER NAME ORUKA THERAPEUTICS, INC. AND TRADE ON NASDAQ UNDER TICKER SYMBOL "ORKA"

* ARCA BIOPHARMA INC: PRE-CLOSING PRIVATE FINANCING OF APPROXIMATELY $275 MILLION ANTICIPATED TO FUND OPERATIONS THROUGH 2027

* ARCA BIOPHARMA INC - PRE-MERGER ORUKA STOCKHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 97.62% OF COMBINED COMPANY

* ARCA BIOPHARMA INC - ARCA IS EXPECTED TO CONTRIBUTE $5 MILLION TO COMBINED ENTITY

* ARCA BIOPHARMA INC: PRE-CLOSING PRIVATE FINANCING OF APPROXIMATELY $275 MILLION ANTICIPATED TO FUND OPERATIONS THROUGH 2027

* ARCA BIOPHARMA INC - EXPECTS TO PAY A DIVIDEND TO PRE-MERGER ARCA STOCKHOLDERS OF APPROXIMATELY $20 MILLION IMMEDIATELY PRIOR TO CLOSE OF MERGER

* ARCA BIOPHARMA INC - COMBINED COMPANY WILL BE NAMED ORUKA THERAPEUTICS, INC. AND LED BY LAWRENCE KLEIN, ORUKA'S CURRENT CHIEF EXECUTIVE OFFICER

* ARCA BIOPHARMA INC: EXPECTS TO DECLARE A CASH DIVIDEND TO PRE-MERGER ARCA STOCKHOLDERS EQUAL TO AMOUNT BY WHICH ARCA'S NET CASH EXCEEDS $5 MILLION.

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2424881491"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2424881491\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2424881491?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-03 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2424881491","market":"us","top_or_hot":-1,"title":"BRIEF-ARCA Biopharma And Oruka Therapeutics Announce Merger Agreement","media":"Reuters","content":"<html><body><p>April 3 (Reuters) - ARCA Biopharma Inc   :</p><p>   * ARCA BIOPHARMA AND ORUKA THERAPEUTICS ANNOUNCE MERGER AGREEMENT</p><p>   * ARCA BIOPHARMA AND ORUKA THERAPEUTICS ANNOUNCE MERGER AGREEMENT</p><p>   * ARCA BIOPHARMA INC - UNDER TERMS OF MERGER AGREEMENT, PRE-MERGER ARCA STOCKHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 2.38% OF COMBINED COMPANY</p><p>   * ARCA BIOPHARMA INC - COMBINED COMPANY PLANS TO OPERATE UNDER NAME ORUKA THERAPEUTICS, INC. AND TRADE ON NASDAQ UNDER TICKER SYMBOL \"ORKA\"</p><p>   * ARCA BIOPHARMA INC: PRE-CLOSING PRIVATE FINANCING OF APPROXIMATELY $275 MILLION ANTICIPATED TO FUND OPERATIONS THROUGH 2027</p><p>   * ARCA BIOPHARMA INC - PRE-MERGER ORUKA STOCKHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 97.62% OF COMBINED COMPANY</p><p>   * ARCA BIOPHARMA INC - ARCA IS EXPECTED TO CONTRIBUTE $5 MILLION TO COMBINED ENTITY</p><p>   * ARCA BIOPHARMA INC: PRE-CLOSING PRIVATE FINANCING OF APPROXIMATELY $275 MILLION ANTICIPATED TO FUND OPERATIONS THROUGH 2027</p><p>   * ARCA BIOPHARMA INC - EXPECTS TO PAY A DIVIDEND TO PRE-MERGER ARCA STOCKHOLDERS OF APPROXIMATELY $20 MILLION IMMEDIATELY PRIOR TO CLOSE OF MERGER</p><p>   * ARCA BIOPHARMA INC - COMBINED COMPANY WILL BE NAMED ORUKA THERAPEUTICS, INC. AND LED BY LAWRENCE KLEIN, ORUKA'S CURRENT CHIEF EXECUTIVE OFFICER</p><p>   * ARCA BIOPHARMA INC: EXPECTS TO DECLARE A CASH DIVIDEND TO PRE-MERGER ARCA STOCKHOLDERS EQUAL TO AMOUNT BY WHICH ARCA'S NET CASH EXCEEDS $5 MILLION.</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-ARCA Biopharma And Oruka Therapeutics Announce Merger Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-ARCA Biopharma And Oruka Therapeutics Announce Merger Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-04-03 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>April 3 (Reuters) - ARCA Biopharma Inc   :</p><p>   * ARCA BIOPHARMA AND ORUKA THERAPEUTICS ANNOUNCE MERGER AGREEMENT</p><p>   * ARCA BIOPHARMA AND ORUKA THERAPEUTICS ANNOUNCE MERGER AGREEMENT</p><p>   * ARCA BIOPHARMA INC - UNDER TERMS OF MERGER AGREEMENT, PRE-MERGER ARCA STOCKHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 2.38% OF COMBINED COMPANY</p><p>   * ARCA BIOPHARMA INC - COMBINED COMPANY PLANS TO OPERATE UNDER NAME ORUKA THERAPEUTICS, INC. AND TRADE ON NASDAQ UNDER TICKER SYMBOL \"ORKA\"</p><p>   * ARCA BIOPHARMA INC: PRE-CLOSING PRIVATE FINANCING OF APPROXIMATELY $275 MILLION ANTICIPATED TO FUND OPERATIONS THROUGH 2027</p><p>   * ARCA BIOPHARMA INC - PRE-MERGER ORUKA STOCKHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 97.62% OF COMBINED COMPANY</p><p>   * ARCA BIOPHARMA INC - ARCA IS EXPECTED TO CONTRIBUTE $5 MILLION TO COMBINED ENTITY</p><p>   * ARCA BIOPHARMA INC: PRE-CLOSING PRIVATE FINANCING OF APPROXIMATELY $275 MILLION ANTICIPATED TO FUND OPERATIONS THROUGH 2027</p><p>   * ARCA BIOPHARMA INC - EXPECTS TO PAY A DIVIDEND TO PRE-MERGER ARCA STOCKHOLDERS OF APPROXIMATELY $20 MILLION IMMEDIATELY PRIOR TO CLOSE OF MERGER</p><p>   * ARCA BIOPHARMA INC - COMBINED COMPANY WILL BE NAMED ORUKA THERAPEUTICS, INC. AND LED BY LAWRENCE KLEIN, ORUKA'S CURRENT CHIEF EXECUTIVE OFFICER</p><p>   * ARCA BIOPHARMA INC: EXPECTS TO DECLARE A CASH DIVIDEND TO PRE-MERGER ARCA STOCKHOLDERS EQUAL TO AMOUNT BY WHICH ARCA'S NET CASH EXCEEDS $5 MILLION.</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2424881491","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2424881491","pubTimestamp":1712145660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"April 3 (Reuters) - ARCA Biopharma Inc   :   * ARCA BIOPHARMA AND ORUKA THERAPEUTICS ANNOUNCE MERGER AGREEMENT   * ARCA BIOPHARMA AND ORUKA THERAPEUTICS ANNOUNCE MERGER AGREEMENT   * ARCA BIOPHARMA IN","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LENZ":"Therapeutics"},"translate_title":"简介—ARCA Biopharma与Oruka Therapeutics宣布合并协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABIO":0.9,"LENZ":1},"content_text":"April 3 (Reuters) - ARCA Biopharma Inc   :   * ARCA BIOPHARMA AND ORUKA THERAPEUTICS ANNOUNCE MERGER AGREEMENT   * ARCA BIOPHARMA AND ORUKA THERAPEUTICS ANNOUNCE MERGER AGREEMENT   * ARCA BIOPHARMA INC - UNDER TERMS OF MERGER AGREEMENT, PRE-MERGER ARCA STOCKHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 2.38% OF COMBINED COMPANY   * ARCA BIOPHARMA INC - COMBINED COMPANY PLANS TO OPERATE UNDER NAME ORUKA THERAPEUTICS, INC. AND TRADE ON NASDAQ UNDER TICKER SYMBOL \"ORKA\"   * ARCA BIOPHARMA INC: PRE-CLOSING PRIVATE FINANCING OF APPROXIMATELY $275 MILLION ANTICIPATED TO FUND OPERATIONS THROUGH 2027   * ARCA BIOPHARMA INC - PRE-MERGER ORUKA STOCKHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 97.62% OF COMBINED COMPANY   * ARCA BIOPHARMA INC - ARCA IS EXPECTED TO CONTRIBUTE $5 MILLION TO COMBINED ENTITY   * ARCA BIOPHARMA INC: PRE-CLOSING PRIVATE FINANCING OF APPROXIMATELY $275 MILLION ANTICIPATED TO FUND OPERATIONS THROUGH 2027   * ARCA BIOPHARMA INC - EXPECTS TO PAY A DIVIDEND TO PRE-MERGER ARCA STOCKHOLDERS OF APPROXIMATELY $20 MILLION IMMEDIATELY PRIOR TO CLOSE OF MERGER   * ARCA BIOPHARMA INC - COMBINED COMPANY WILL BE NAMED ORUKA THERAPEUTICS, INC. AND LED BY LAWRENCE KLEIN, ORUKA'S CURRENT CHIEF EXECUTIVE OFFICER   * ARCA BIOPHARMA INC: EXPECTS TO DECLARE A CASH DIVIDEND TO PRE-MERGER ARCA STOCKHOLDERS EQUAL TO AMOUNT BY WHICH ARCA'S NET CASH EXCEEDS $5 MILLION.Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}